FBLG Stock Forecast: FibroBiologics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.71
−15.06% on the day

The median 12-month analyst price target for FibroBiologics, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 64 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$6.3M
Ticker Nerd rank
64/ 100
Median analyst target
$12
Analysts covering
2
Revenue$0.0
Operating income−$4.0M
Net income−$4.1M
Free cash flow−$3.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−23.9%
1M
−23.4%
YTD
−84.3%
1Y
−89.2%
From 52W high
−91.9%
From 52W low
+12.4%
$0.63
$8.70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores FibroBiologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
64/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
85
Revisions
82
Accruals
74
Issuance
59
Volatility
45
Value
22
Momentum
18
Quality
15

Growth (85): Sales and profits are climbing, and climbing faster than before.

Quality (15): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FBLG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FBLG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26FBLGHigh $19Median $12Low $4

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1
Buy
1
Hold
0
Sell
$4
Low
$12
Median
$19
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Nov 2026HC Wainwright & Co.MaintainsBuy$6.00 → $4.00
4 Aug 2026HC Wainwright & Co.MaintainsBuy$8.00 → $6.00
4 May 2026Maxim GroupDowngradeHold—
16 Apr 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026D. Boral CapitalDowngradeHold—
12 Mar 2026D. Boral CapitalMaintainsBuy—
26 Feb 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026D. Boral CapitalMaintainsBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
2 Jan 2026HC Wainwright & Co.ReiteratesBuy—
20 Nov 2025D. Boral CapitalMaintainsBuy—
5 Nov 2025HC Wainwright & Co.MaintainsBuy—
3 Nov 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025HC Wainwright & Co.ReiteratesBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
5 Aug 2025HC Wainwright & Co.MaintainsBuy—
4 Aug 2025D. Boral CapitalMaintainsBuy—
29 July 2025D. Boral CapitalMaintainsBuy—
9 July 2025D. Boral CapitalMaintainsBuy—
17 June 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FBLG.

Market Radar

This page is one stock. Monday covers all of them.

FBLG appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FBLG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, FibroBiologics, Inc. returned −89.2% against +6.9% for the S&P 500, dividends included.

FBLG vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120140Jan 26Apr 26Jul 26Oct 26FBLGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FBLG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
3.2×

Cheaper than 28% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−1696.9%

Higher than 1% of US stocks

Return on assets
−127.2%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • FibroBiologics, Inc. has a market value of $6.3M and an enterprise value of $6.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$18.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$14.8M.

  • Shares outstanding: 6.1M.

  • FibroBiologics, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

FBLG and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FBLGFibroBiologics, Inc.$6.3M64
KYNBKyntra Bio, Inc.$6.3M41
ACXPAcurx Pharmaceuticals, Inc.$6.3M18
CNSYCerenome, Inc.$6.2M13
GTBPGT Biopharma, Inc.$6.1M13
ENVBEnveric Biosciences, Inc.$6.0M16
MTVAMetaVia, Inc.$6.7M10

Take a look at FBLG’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own FibroBiologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about FBLG

What is the FBLG stock price forecast for 2026-2027?

The median 12-month analyst price target for FibroBiologics, Inc. is $12, with estimates ranging from $4 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FBLG stock a buy right now?

Of the 2 analysts covering FibroBiologics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks FibroBiologics, Inc. 64 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FBLG?

As at 21 Nov 2026, FibroBiologics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).

Will FBLG stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $12, and Ticker Nerd's factor model ranks FibroBiologics, Inc. 64 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FBLG stock forecast for 2030?

No analyst covering FibroBiologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FBLG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $19 over the next 12 months.

How has FBLG stock performed over the past year?

FibroBiologics, Inc. returned -89.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does FibroBiologics, Inc. do?

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases. Its current programs center on regenerative medicine and cell therapy applications for conditions such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers.

Company

About FibroBiologics, Inc.

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based therapies for chronic diseases. Its current programs center on regenerative medicine and cell therapy applications for conditions such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers. The company’s pipeline includes product candidates such as CYWC628, CYMS101, CYPS317, and CybroCell, which are being developed to address areas of significant unmet medical need. FibroBiologics also works with fibroblast cells and fibroblast-derived materials in research programs related to tissue regeneration and immune modulation. Based in Houston, Texas, FibroBiologics plays a specialized role in the biotechnology market by advancing cell-based approaches designed for therapeutic use across several disease areas.

CEO Mr. Peter O'Heeron · 15 employees · United States · https://fibrobiologics.com